SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised outlook have been overshadowed by a sharp post-earnings selloff, with traders citing negative cash flow, heavy investment needs, and a demanding valuation despite demand for data-center power. Bulls view the spending as investment in growth and are buying the dip, while skeptics question whether that growth will translate into cash.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a prolonged slide toward record lows, with traders debating whether the Trump-linked company has lasting value beyond political and crypto-related speculation. The discussion is largely bearish, citing weak business fundamentals and midterm-election risks, while a smaller group sees potential for a rebound on Trump-related headlines.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Keytruda, which showed a reduced risk of recurrence or death, have driven intense trading after the shares fell sharply in a sell-the-news reaction to leaked data following a major run-up. Traders are split between viewing the results as meaningful validation of the cancer-vaccine platform and arguing they fell short of lofty expectations or leave commercial questions unresolved; volatile rebounds and reversals are also a major focus.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics MSToronto presentationsparticularly preliminary Phase 1 azer-cel data in progressive MS with encouraging safety and early clinical signalsare driving attention, alongside long-term BRIUMVI and dosing updates. Traders praise the science but debate the muted stock reaction, noting azer-cel remains early-stage and pointing to BRIUMVI subcutaneous Phase 3 data and earnings as upcoming catalysts.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

FIGR is drawing attention after a steep, persistent selloff, with bearish traders pointing to insider share sales, CEO trust concerns and weak price action; some also speculate about further declines or short pressure. Bulls counter that loan-marketplace growth, earnings and the companys tokenization ambitions support the business, leaving the debate focused on whether those prospects outweigh selling pressure and valuation concerns.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Iran and wider Middle East tensions could disrupt oil supplies and shipping, particularly through the Strait of Hormuz. Traders are split between riding the breakout and expecting a sharp pullback, with sentiment sensitive to shifting war and peace headlines.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs continued slide to deeply depressed levels has traders focused on concerns about a possible distribution cut, unit dilution, and Icahn Enterprises weakening value and management credibility. Some holders argue its CVR Energy stake and high short interest could support a rebound, while others see further downside risk and are waiting for earnings or clearer action from management.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto is drawing attention after a sharp rebound from recent lows, as traders connect renewed cybersecurity-sector strength to AI-driven threat concerns and newly disclosed PHP vulnerabilities. Bulls see durable security demand, while skeptics warn the rally may fade and cite stretched valuation.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

BDR Pharmaceuticals is challenging the FDAs refusal to accept a generic application referencing VOQUEZNA, putting the drugs exclusivity through 2032 in focus and weighing on PHAT shares. Traders debate the risk of an earlier generic and a prolonged legal overhang against the view that the FDAs prior ruling supports Phathoms position and sales can keep growing during litigation.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFibers convertible senior notes offering has driven a sharp selloff, as traders worry about potential dilution and hedging pressure. Some see the financing as funding for data-center expansion, while others question whether future growth will translate into value for shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices (MASS) delivered earnings and revenue surprises of +21.43% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

InspireMD NSPR Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of +15.79% and +25.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance

Equity

The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.


InspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?

InspireMD (NYSE:NSPR) Stock Price Up 3.5% - Here's What Happened...

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

InspireMD Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck — who led the earlier study — will head the new trial.</li><li>Separately, the company also announced that it has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid stent delivery system.</li><li>The company also withdrew its full-year 2026 revenue guidance.</li></ul>&nbsp;Shares of InspireMD (NSPR) jumped 30% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its application to start the CGUARDIANS III pivotal study of the SwitchGuard Neuro-Protection System, overshadowing the pessimism around the firm dropping its 2026 financial guidance.The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures. The device reverses blood flow to catch debris and help prevent strokes in patients with carotid artery disease.Vascular surgeons Dr. Patrick Geraghty and Dr. Patrick Muck — who led the earlier study — will head the new trial.“This is an important step toward offering a complete TCAR solution,” said CEO Marvin Slosman. The company hopes to launch SwitchGuard in the U.S. in 2027 if approved.InspireMD already won FDA approval for its CGuard Prime stent in June 2025.<h2 class="st-heading-2">Recall And Dropped Guidance</h2>Separately, the company also announced that it has initiated a voluntary recall in the U.S. for its CGuard Prime 135 cm carotid stent delivery system.The company said the delivery system did not meet technical performance expectations during a controlled commercial launch for carotid artery stenting (CAS) procedures. The recall applies only to the delivery system and does not affect the CGuard stent implant itself.There are no safety concerns for patients who have already received the implanted stent. InspireMD is pausing U.S. sales of the 135 cm version while it makes design improvements. The company expects FDA approval for the original CGuard delivery system in the third quarter of 2026 and for the enhanced Prime version in the first half of 2027. As a result, it has withdrawn its full-year 2026 revenue guidance.“Management believes this is the most prudent step given the impact of the temporary discontinuation of commercial activity in the U.S. pending the anticipated FDA approval of its original CGuard stent delivery system in the third quarter of 2026,” the company said.More details will be provided at the company’s first quarter earnings on May 4, InspireMD added.<h2 class="st-heading-2">How Did NSPR Retail Traders React?</h2>On Stocktwits, retail sentiment around NSPR stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.A Stocktwits user expressed skepticism about upcoming dilution.<stembedurl>https://www.stocktwits.com/Thespectator/message/652062806</stembedurl>Another user dismissed the application news as nothing more than regular updates from biotech companies.<stembedurl>https://www.stocktwits.com/vcaelum/message/652062730</stembedurl><a href="https://stocktwits.com/symbol/NSPR">NSPR stock</a> has fallen 56% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-uone-stock-rally-38-percent-today/cZQVLLCReeY">Why Did UONE Stock Rally 38% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Beam Global rose premarket on Thursday. (Representative image: Getty Images)

The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.

iShares Micro-Cap ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.4479
Prev Close	$0.455
Open	$0.47
Dividend Yield	0.00%
50-Day Moving Average	$0.7172
Beta	0.38
Avg. Volume	57,146.38
PE Ratio	-0.70

52-Week High	$2.41
52-Week Low	$0.4254
Market Capitalization	$21.15M
EPS (Annual)	-$0.7584
Price to Book	0.68
Revenue Per Employee	$70,700.79

Feed

News

Sentiment

Earnings

Fundamentals

Info

NSPR Fundamentals